Logo image of IMTX

IMMATICS NV (IMTX) Stock Fundamental Analysis

NASDAQ:IMTX - Nasdaq - NL0015285941 - Common Stock - Currency: USD

5.11  -0.09 (-1.73%)

After market: 5.11 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IMTX. IMTX was compared to 562 industry peers in the Biotechnology industry. IMTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, IMTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

IMTX had negative earnings in the past year.
IMTX had a negative operating cash flow in the past year.
In multiple years IMTX reported negative net income over the last 5 years.
In multiple years IMTX reported negative operating cash flow during the last 5 years.
IMTX Yearly Net Income VS EBIT VS OCF VS FCFIMTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

IMTX has a better Return On Assets (2.19%) than 91.64% of its industry peers.
IMTX has a better Return On Equity (2.65%) than 92.53% of its industry peers.
Industry RankSector Rank
ROA 2.19%
ROE 2.65%
ROIC N/A
ROA(3y)-2.39%
ROA(5y)-28.72%
ROE(3y)-7.75%
ROE(5y)-130.43%
ROIC(3y)N/A
ROIC(5y)N/A
IMTX Yearly ROA, ROE, ROICIMTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

With an excellent Profit Margin value of 9.76%, IMTX belongs to the best of the industry, outperforming 93.06% of the companies in the same industry.
The Operating Margin and Gross Margin are not available for IMTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 9.76%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMTX Yearly Profit, Operating, Gross MarginsIMTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

IMTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IMTX has been increased compared to 5 years ago.
The debt/assets ratio for IMTX has been reduced compared to a year ago.
IMTX Yearly Shares OutstandingIMTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
IMTX Yearly Total Debt VS Total AssetsIMTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

IMTX has an Altman-Z score of 2.54. This is not the best score and indicates that IMTX is in the grey zone with still only limited risk for bankruptcy at the moment.
IMTX has a better Altman-Z score (2.54) than 74.56% of its industry peers.
IMTX has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.02, IMTX perfoms like the industry average, outperforming 40.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 2.54
ROIC/WACCN/A
WACC7.07%
IMTX Yearly LT Debt VS Equity VS FCFIMTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

IMTX has a Current Ratio of 9.26. This indicates that IMTX is financially healthy and has no problem in meeting its short term obligations.
IMTX has a better Current ratio (9.26) than 76.51% of its industry peers.
IMTX has a Quick Ratio of 9.26. This indicates that IMTX is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 9.26, IMTX is doing good in the industry, outperforming 76.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.26
Quick Ratio 9.26
IMTX Yearly Current Assets VS Current LiabilitesIMTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 84.54% over the past year.
IMTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 188.60%.
The Revenue has been growing by 53.31% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)84.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1000%
Revenue 1Y (TTM)188.6%
Revenue growth 3Y64.83%
Revenue growth 5Y53.31%
Sales Q2Q%-38.61%

3.2 Future

Based on estimates for the next years, IMTX will show a very negative growth in Earnings Per Share. The EPS will decrease by -52.56% on average per year.
Based on estimates for the next years, IMTX will show a quite strong growth in Revenue. The Revenue will grow by 13.50% on average per year.
EPS Next Y-975.84%
EPS Next 2Y-231.1%
EPS Next 3Y-130.63%
EPS Next 5Y-52.56%
Revenue Next Year-48.65%
Revenue Next 2Y-26.44%
Revenue Next 3Y-12.51%
Revenue Next 5Y13.5%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
IMTX Yearly Revenue VS EstimatesIMTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
IMTX Yearly EPS VS EstimatesIMTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMTX. In the last year negative earnings were reported.
Also next year IMTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMTX Price Earnings VS Forward Price EarningsIMTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMTX Per share dataIMTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

IMTX's earnings are expected to decrease with -130.63% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-231.1%
EPS Next 3Y-130.63%

More info and screens

0

5. Dividend

5.1 Amount

IMTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMATICS NV

NASDAQ:IMTX (5/23/2025, 8:25:15 PM)

After market: 5.11 0 (0%)

5.11

-0.09 (-1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners72.1%
Inst Owner Change-1.74%
Ins Owners3.64%
Ins Owner ChangeN/A
Market Cap621.12M
Analysts87.69
Price Target15.56 (204.5%)
Short Float %6.2%
Short Ratio7.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)148.01%
Min EPS beat(2)69.24%
Max EPS beat(2)226.79%
EPS beat(4)4
Avg EPS beat(4)105.9%
Min EPS beat(4)41.72%
Max EPS beat(4)226.79%
EPS beat(8)7
Avg EPS beat(8)53.05%
EPS beat(12)8
Avg EPS beat(12)29.27%
EPS beat(16)8
Avg EPS beat(16)4.27%
Revenue beat(2)2
Avg Revenue beat(2)236.15%
Min Revenue beat(2)207.52%
Max Revenue beat(2)264.77%
Revenue beat(4)4
Avg Revenue beat(4)137.99%
Min Revenue beat(4)34.4%
Max Revenue beat(4)264.77%
Revenue beat(8)6
Avg Revenue beat(8)62.05%
Revenue beat(12)8
Avg Revenue beat(12)44.51%
Revenue beat(16)8
Avg Revenue beat(16)23.11%
PT rev (1m)-4.19%
PT rev (3m)-2.14%
EPS NQ rev (1m)8.02%
EPS NQ rev (3m)-54.76%
EPS NY rev (1m)-3.66%
EPS NY rev (3m)-15.34%
Revenue NQ rev (1m)1.16%
Revenue NQ rev (3m)-33.45%
Revenue NY rev (1m)-9.67%
Revenue NY rev (3m)-6.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.53
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 0.96
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-1.62
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS1.45
BVpS5.34
TBVpS5.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.19%
ROE 2.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 9.76%
GM N/A
FCFM N/A
ROA(3y)-2.39%
ROA(5y)-28.72%
ROE(3y)-7.75%
ROE(5y)-130.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 134.81%
Cap/Sales 10.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.26
Quick Ratio 9.26
Altman-Z 2.54
F-Score6
WACC7.07%
ROIC/WACCN/A
Cap/Depr(3y)217.11%
Cap/Depr(5y)185.86%
Cap/Sales(3y)23.83%
Cap/Sales(5y)22.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1000%
EPS Next Y-975.84%
EPS Next 2Y-231.1%
EPS Next 3Y-130.63%
EPS Next 5Y-52.56%
Revenue 1Y (TTM)188.6%
Revenue growth 3Y64.83%
Revenue growth 5Y53.31%
Sales Q2Q%-38.61%
Revenue Next Year-48.65%
Revenue Next 2Y-26.44%
Revenue Next 3Y-12.51%
Revenue Next 5Y13.5%
EBIT growth 1Y62.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-88.17%
EBIT Next 3Y-52.74%
EBIT Next 5Y-16.76%
FCF growth 1Y-1270.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-966.96%
OCF growth 3YN/A
OCF growth 5YN/A